GLP-1 Drugs Like Semaglutide Could Cut Heart Disease Risk by 22% in High-Risk Adults
A large emulation study finds semaglutide-class drugs may reduce 10-year cardiovascular events by nearly 3% absolute in high-risk, obese, CVD-free adults.
Résumé
Researchers used data from over 800,000 Europeans and North Americans to model what would happen if high-risk, obese adults without existing heart disease took GLP-1 receptor agonists like semaglutide. By applying the risk factor changes seen in the SELECT trial to real-world survey populations, they projected a 22% relative reduction in 10-year cardiovascular disease incidence — translating to roughly 3 fewer events per 100 people over a decade. Men showed slightly larger absolute benefits than women, though relative reductions were similar. Benefits shrank in lower-risk or non-obese groups and when accounting for imperfect medication adherence. The findings support expanding GLP-1 therapy into primary prevention, but authors stress randomized trials are needed to confirm real-world benefit.
Résumé détaillé
GLP-1 receptor agonists (GLP-1RAs) such as semaglutide have already demonstrated cardiovascular benefits in obese patients with established heart disease. But a critical unanswered question remains: can these drugs also prevent first cardiovascular events in high-risk people who haven't yet developed disease?
This study tackled that question using a trial emulation approach. Investigators built a cardiovascular risk model from 610,789 CVD-free individuals drawn from the Global Cardiovascular Risk Consortium, incorporating five key risk factors — BMI, HbA1c, systolic blood pressure, high-sensitivity CRP, and non-HDL cholesterol. They then applied the sex-specific, placebo-adjusted changes in those risk factors observed in the SELECT semaglutide trial to 200,012 individuals from two large contemporary health surveys.
Among the 21,720 survey participants with BMI ≥27 and elevated baseline cardiovascular risk (SCORE2 ≥7.5%), emulated GLP-1RA therapy reduced projected 10-year CVD incidence from 13.82% to 10.83% — an absolute reduction of 2.99% and a relative reduction of 22%. Men experienced slightly larger absolute reductions (3.14%) compared to women (2.70%), though relative risk reductions were comparable across sexes at roughly 21–23%.
Importantly, benefits were significantly attenuated in non-obese individuals and those at lower baseline cardiovascular risk, and diminished further when realistic assumptions about medication non-compliance were applied. This underscores the importance of patient selection for maximizing the preventive impact of these agents.
The study carries notable caveats — it is an emulation, not a randomized trial, and is co-funded by Novo Nordisk, the maker of semaglutide. The findings nonetheless provide a compelling quantitative rationale for dedicated primary prevention trials of GLP-1RAs in appropriately selected high-risk populations.
Principales conclusions
- Emulated semaglutide therapy reduced 10-year CVD incidence by 22% relatively and ~3% absolutely in high-risk obese adults.
- Men showed slightly larger absolute risk reductions (3.14%) than women (2.70%), with similar relative reductions (~21–23%).
- Benefits were substantially attenuated in non-obese individuals and those with lower baseline cardiovascular risk.
- Lower medication compliance assumptions further diminished projected risk reductions.
- Results support rationale for randomized primary prevention trials of GLP-1RAs in high-risk, obese populations.
Méthodologie
The study used a trial emulation design, fitting a 10-year CVD risk model on 610,789 CVD-free individuals from the Global Cardiovascular Risk Consortium, then applying sex-stratified, placebo-adjusted risk factor changes from the SELECT RCT to 200,012 individuals in two contemporary health examination surveys. Primary analyses focused on individuals with BMI ≥27 and SCORE2-derived baseline risk ≥7.5%.
Limites de l'étude
This is a modeled emulation rather than a randomized controlled trial, so causal inference is limited. The study was co-funded by Novo Nordisk via an unrestricted grant, introducing potential funding bias despite reported independence. Risk factor changes were borrowed from a trial population that may not perfectly match general survey populations.
Ce résumé vous a plu ?
Recevez les dernières recherches sur la longévité dans votre boîte de réception chaque semaine.
Saisissez votre e-mail pour vous abonner :